Live
FierceBiotechRoche nabs European approval for second Eli Lilly-partnered Alzheimer’s testPfizerPfizer Ltd stock (INE182A01018): Indian pharma subsidiary eyes growth - AD HOC NEWSWuXi AppTecWuXi AppTec stock (CNE1000009Q7): Bearish block trade signals market caution - AD HOC NEWSMerck & Co.Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma - The Manila TimesFierceBiotechBayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drugBioPharma DiveA year after Vertex’s big launch, pain drug research faces a pivotal momentMerck & Co.Erasca partners with Merck on best-in-class pan-RAS molecular glue - The Pharma LetterEndpoints NewsFlagship startup Serif says it has solved non-viral gene therapy in monkeysFierceBiotechBlood-based approach could detect early heart, kidney disease, study findsEndpoints NewsBristol Myers joins Hengrui party in 13-asset deal worth up to $15.2BMedtronicMedtronic plc stock (IE00BTN1Y115): Global medical device leader with strong US presence - AD HOC NEWSAgilentAgilent expands collaboration with C-CAMP to scale access to advanced life sciences analytics - BioSpectrum India
Endpoints News Mar 26, 2026

Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program

Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program

Original
Body unavailable. Use the original source.